Cancer drug Dostarlimab hailed a breakthrough after curing 12 patients
For the first time in the history of cancer treatments, a new trial gathered a 100% success rate.
Twelve patients were cured of rectal cancer after taking Dostarlimab every three weeks for six months, followed by chemo-radiotherapy and surgery.
The study carried out in the US has been celebrated as groundbreaking, remarkable and unprecedented.
Dostarlimab – an immunotherapy drug – is used in the treatment of endometrial cancer. It unmasks cancer cells, allowing the immune system to conquer and destroy.
Following 6 months of Dostarlimab, doctors waited another 6 months to test patients. The cancer could not be detected on PET or MRI scans.
This is the most prolific breakthrough in cancer treatment.
Read more about the findings here.
WATCH:
View this post on Instagram